The company changed its name from BioTime Inc. to Lineage Cell Therapeutics less than one year following its appointment of a new CEO, Brian Culley, in August 2018 and completing a series of corporate transactions including the distribution of AgeX Therapeutics, the acquisition of Asterias Biotherapeutics and conducting management changes which altogether focused the company mission on developing novel therapies based on directed differentiation and transplant of specific cell types.

[12][13][14] Since then, Lineage’s focus has been to develop therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer.

Specifically, Lineage is testing therapies to treat dry age-related macular degeneration, spinal cord injuries, non-small cell lung cancer, auditory neuropathy, and vision loss.

Preliminary evidence of visual function and outer retinal structure improvements observed in five Cohort 4 patients with GA and impaired vision.

[18] In December 2021, Lineage announced that the company entered a $670 million exclusive worldwide collaboration Genentech, a member of the Roche Group, for the development and commercialization of OpRegen.

[19] ●OPC1, an oligodendrocyte progenitor cell therapy currently in a Phase 1/2a multicenter clinical trial for acute spinal cord injuries (“SCI”).